Progression of advanced breast cancer not delayed by new combination therapy

[News]

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.

More... (http://www.medicalnewstoday.com/releases/270212.php)

['lizbeth]

GDP,

Has Nagourney identified the group that benefits from ramucirumab yet?